Literature DB >> 1325703

Interaction of the human polyomavirus, JCV, with human B-lymphocytes.

W J Atwood1, K Amemiya, R Traub, J Harms, E O Major.   

Abstract

The human polyomavirus, JCV, is the causative agent of the central nervous system demyelinating disease progressive multifocal leukoencephalopathy (PML). The principal target of JCV infection in the central nervous system (CNS) is the myelinating oligodendrocyte. However, the site of JCV multiplication outside of the CNS and the mechanism by which virus gains access to the brain are not known. Recently, JCV infected B-lymphocytes have been demonstrated in PML patients in several lymphoid organs, in circulating peripheral lymphocytes, and in brain, suggesting a possible role of B-lymphocytes in the dissemination of virus to the brain. The experiments reported here were undertaken to understand more about the interactions of JCV with human B-lymphocytes. The data show that JCV is able to multiply in either Epstein-Barr virus transformed (EBV) or EBV negative human B cell lines resulting in production of infectious, progeny virions. In addition, nuclear proteins extracted from these B cells bind to similar nucleotides within the JCV regulatory region that are bound by nuclear proteins extracted from human fetal glial cells, the most susceptible host and principal target cell for JCV infection in vitro. It is not known, however, whether these DNA binding proteins from susceptible B cells and glial cells are similar.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1325703     DOI: 10.1016/0042-6822(92)90909-9

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  49 in total

1.  Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies.

Authors:  C Goldmann; H Petry; S Frye; O Ast; S Ebitsch; K D Jentsch; F J Kaup; F Weber; C Trebst; T Nisslein; G Hunsmann; T Weber; W Lüke
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Increased frequency of JC virus type 2 and of dual infection with JC virus type 1 and 2 in Italian progressive multifocal leukoencephalopathy patients.

Authors:  P Ferrante; M Mediati; R Caldarelli-Stefano; L Losciale; R Mancuso; A E Cagni; R Maserati
Journal:  J Neurovirol       Date:  2001-02       Impact factor: 2.643

Review 3.  Epidemiological evidence and molecular basis of interactions between HIV and JC virus.

Authors:  J R Berger; A Chauhan; D Galey; A Nath
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

Review 4.  Progressive multifocal leukoencephalopathy and newer biological agents.

Authors:  Joseph R Berger
Journal:  Drug Saf       Date:  2010-11-01       Impact factor: 5.606

Review 5.  Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis.

Authors:  Chen S Tan; Igor J Koralnik
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

6.  Monoclonal antibodies and progressive multifocal leukoencephalopathy.

Authors:  Joseph R Berger; Sidney A Houff; Eugene O Major
Journal:  MAbs       Date:  2009 Nov-Dec       Impact factor: 5.857

Review 7.  The immune response to infectious diseases of the central nervous system: a tenuous balance.

Authors:  A R Pachner
Journal:  Springer Semin Immunopathol       Date:  1996

Review 8.  Persistence and pathogenesis of the neurotropic polyomavirus JC.

Authors:  Hassen S Wollebo; Martyn K White; Jennifer Gordon; Joseph R Berger; Kamel Khalili
Journal:  Ann Neurol       Date:  2015-03-06       Impact factor: 10.422

Review 9.  Immune surveillance and response to JC virus infection and PML.

Authors:  Sarah Beltrami; Jennifer Gordon
Journal:  J Neurovirol       Date:  2013-12-03       Impact factor: 2.643

10.  JC virus viremia in interferon-beta -treated and untreated Italian multiple sclerosis patients and healthy controls.

Authors:  Serena Delbue; Franca Rosa Guerini; Roberta Mancuso; Domenico Caputo; Romina Mazziotti; Marina Saresella; Pasquale Ferrante
Journal:  J Neurovirol       Date:  2007       Impact factor: 2.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.